{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:41:14Z","timestamp":1791686474662,"version":"4.3.4"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002860","name":"China Sponsorship Council","doi-asserted-by":"publisher","award":["201607720029"],"award-info":[{"award-number":["201607720029"]}],"id":[{"id":"10.13039\/501100002860","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Development of novel testing strategies to detect adverse human health effects is of interest to replace in vivo-based drug and chemical safety testing. The aim of the present study was to investigate whether physiologically based kinetic (PBK) modeling-facilitated conversion of in vitro toxicity data is an adequate approach to predict in vivo cardiotoxicity in humans. To enable evaluation of predictions made, methadone was selected as the model compound, being a compound for which data on both kinetics and cardiotoxicity in humans are available. A PBK model for methadone in humans was developed and evaluated against available kinetic data presenting an adequate match. Use of the developed PBK model to convert concentration\u2013response curves for the effect of methadone on human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) in the so-called multi electrode array (MEA) assay resulted in predictions for in vivo dose\u2013response curves for methadone-induced cardiotoxicity that matched the available in vivo data. The results also revealed differences in protein plasma binding of methadone to be a potential factor underlying variation between individuals with respect to sensitivity towards the cardiotoxic effects of methadone. The present study provides a proof-of-principle of using PBK modeling-based reverse dosimetry of in vitro data for the prediction of cardiotoxicity in humans, providing a novel testing strategy in cardiac safety studies.<\/jats:p>","DOI":"10.1007\/s00204-020-02766-7","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T07:02:49Z","timestamp":1588575769000},"page":"2809-2827","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Integrating in vitro data and physiologically based kinetic modeling-facilitated reverse dosimetry to predict human cardiotoxicity of methadone"],"prefix":"10.1007","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9159-1461","authenticated-orcid":false,"given":"Miaoying","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Bouwmeester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne M. C. M.","family":"Rietjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije","family":"Strikwold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"2766_CR1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.fct.2016.03.017","volume":"92","author":"R Abdullah","year":"2016","unstructured":"Abdullah R, Alhusainy W, Woutersen J, Rietjens IMCM, Punt A (2016) Predicting points of departure for risk assessment based on in vitro cytotoxicity data and physiologically based kinetic (PBK) modeling: the case of kidney toxicity induced by aristolochic acid I. Food Chem Toxicol 92:104\u2013116","journal-title":"Food Chem Toxicol"},{"key":"2766_CR2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/clpt.1982.217","volume":"32","author":"FP Abramson","year":"1982","unstructured":"Abramson FP (1982) Methadone plasma protein binding: alterations in cancer and displacement from \u03b11-acid glycoprotein. Clin Pharmacol Ther 32:652\u2013658","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/jat\/20.6.362","volume":"20","author":"ME Alburges","year":"1996","unstructured":"Alburges ME, Huang W, Foltz RL, Moody DE (1996) Determination of methadone and its N-demethylation metabolites in biological specimens by GC-PICI-MS. J Anal Toxicol 20:362\u2013368","journal-title":"J Anal Toxicol"},{"key":"2766_CR5","first-page":"577","volume":"14","author":"S Alinejad","year":"2015","unstructured":"Alinejad S, Kazemi T, Zamani N, Hoffman RS, Mehrpour O (2015) A systematic review of the cardiotoxicity of methadone. EXCLI J 14:577","journal-title":"EXCLI J"},{"key":"2766_CR6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1360-0443.2009.02549.x","volume":"104","author":"K Anchersen","year":"2009","unstructured":"Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H (2009) Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 104:993\u2013999","journal-title":"Addiction"},{"key":"2766_CR7","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.vascn.2016.12.003","volume":"84","author":"H Ando","year":"2017","unstructured":"Ando H et al (2017) A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods 84:111\u2013127","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2766_CR8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/cpt1975173258","volume":"17","author":"E \u00c5ngg\u00e5rd","year":"1975","unstructured":"\u00c5ngg\u00e5rd E, Gunne L-M, Holmstrand J, McMahon RE, Sandberg C-G, Sullivan HR (1975) Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 17:258\u2013266","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2766_CR9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinternmed.2010.26","volume":"170","author":"N Ansermot","year":"2010","unstructured":"Ansermot N et al (2010) Substitution of (R, S)-methadone by (R)-methadone: impact on QTc interval. Arch Intern Med 170(6):529\u2013536","journal-title":"Arch Intern Med"},{"key":"2766_CR10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vascn.2015.04.002","volume":"75","author":"K Asakura","year":"2015","unstructured":"Asakura K et al (2015) Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes. J Pharmacol Toxicol Methods 75:17\u201326","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2766_CR11","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.drugalcdep.2019.03.013","volume":"200","author":"RK Badhan","year":"2019","unstructured":"Badhan RK, Gittins R, Al Zabit D (2019) The optimization of methadone dosing whilst treating with rifampicin: a pharmacokinetic modeling study. Drug Alcohol Depend 200:168\u2013180","journal-title":"Drug Alcohol Depend"},{"key":"2766_CR12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.00797-09","volume":"54","author":"A Barrail-Tran","year":"2010","unstructured":"Barrail-Tran A et al (2010) Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob Agents Chemother 54:614\u2013619","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/138920007779315053","volume":"8","author":"ZE Barter","year":"2007","unstructured":"Barter ZE et al (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro-somal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33\u201345","journal-title":"Curr Drug Metab"},{"key":"2766_CR14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ADM.0000000000000353","volume":"11","author":"G Bart","year":"2017","unstructured":"Bart G, Wyman Z, Wang Q, Hodges JS, Karim R, Bart BA (2017) Methadone and the QTc interval: paucity of clinically significant factors in a retrospective cohort. J Addict Med 11:489","journal-title":"J Addict Med"},{"key":"2766_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.tiv.2017.11.016","volume":"47","author":"SM Bell","year":"2018","unstructured":"Bell SM et al (2018) vitro to in vivo extrapolation for high throughput prioritization and decision making. Toxicol Vitro 47:213\u2013227","journal-title":"Toxicol Vitro"},{"key":"2766_CR16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/jps.10539","volume":"93","author":"LM Berezhkovskiy","year":"2004","unstructured":"Berezhkovskiy LM (2004) Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 93:364\u2013374","journal-title":"J Pharm Sci"},{"key":"2766_CR17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1742-7843.2005.pto960306.x","volume":"96","author":"U Bernauer","year":"2005","unstructured":"Bernauer U, Oberemm A, Madle S, Gundert-Remy U (2005) The use of in vitro data in risk assessment. Basic Clin Pharmacol Toxicol 96:176\u2013181","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2766_CR18","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/10937404.2010.483940","volume":"13","author":"BJ Blaauboer","year":"2010","unstructured":"Blaauboer BJ (2010) Biokinetic modeling and in vitro\u2013in vivo extrapolations. J Toxicol Environ Health Part B 13:242\u2013252","journal-title":"J Toxicol Environ Health Part B"},{"key":"2766_CR19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.116793","volume":"70","author":"DW Boulton","year":"2001","unstructured":"Boulton DW, Arnaud P, DeVane CL (2001) Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther 70:48\u201357","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR20","unstructured":"British Columbia Centre on Substance Use (BCCSU) (2017) A guideline for the clinical management of opioid use disorder. https:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/06\/BC-OUD-Guidelines_June2017.pdf. Accessed 20 Nov 2019"},{"key":"2766_CR21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/074823379701300401","volume":"13","author":"RP Brown","year":"1997","unstructured":"Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407\u2013484","journal-title":"Toxicol Ind Health"},{"key":"2766_CR22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40291-015-0137-4","volume":"19","author":"JF Carlquist","year":"2015","unstructured":"Carlquist JF et al (2015) A possible mechanistic link between the CYP2C19 genotype, the methadone metabolite ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP), and methadone-induced corrected QT interval prolongation in a pilot study. Mol Diagn Ther 19:131\u2013138","journal-title":"Mol Diagn Ther"},{"key":"2766_CR23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1540-8167.2011.02231.x","volume":"23","author":"KC Chang","year":"2012","unstructured":"Chang KC et al (2012) Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. J Cardiovasc Electrophysiol 23:527\u2013533","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2766_CR24","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jat.1225","volume":"27","author":"WA Chiu","year":"2007","unstructured":"Chiu WA et al (2007) Evaluation of physiologically based pharmacokinetic models for use in risk assessment. J Appl Toxicol 27:218\u2013237","journal-title":"J Appl Toxicol"},{"key":"2766_CR25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpain.2014.01.494","volume":"15","author":"R Chou","year":"2014","unstructured":"Chou R et al (2014) Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 15:321\u2013337","journal-title":"J Pain"},{"key":"2766_CR26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1755-5922.12120","volume":"33","author":"M Chowdhury","year":"2015","unstructured":"Chowdhury M, Wong J, Cheng A, Khilkin M, Palma E (2015) Methadone therapy in underserved urban community: QT c Prolongation and life-threatening ventricular arrhythmias. Cardiovasc Ther 33:127\u2013133","journal-title":"Cardiovasc Ther"},{"key":"2766_CR27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/toxsci\/kfv180","volume":"148","author":"M Clements","year":"2015","unstructured":"Clements M, Millar V, Williams AS, Kalinka S (2015) Bridging functional and structural cardiotoxicity assays using human embryonic stem cell-derived cardiomyocytes for a more comprehensive risk assessment. Toxicol Sci 148:241\u2013260","journal-title":"Toxicol Sci"},{"key":"2766_CR28","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jpainsymman.2004.06.012","volume":"29","author":"RA Cruciani","year":"2005","unstructured":"Cruciani RA et al (2005) Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manag 29:385\u2013391","journal-title":"J Pain Symptom Manag"},{"key":"2766_CR29","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF00194951","volume":"48","author":"J De Vos","year":"1995","unstructured":"De Vos J, Ufkes J, van Wilgenburg H, Geerlings P, van den Brink W (1995) Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 48:361\u2013366","journal-title":"Eur J Clin Pharmacol"},{"key":"2766_CR30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/jat\/bku096","volume":"38","author":"SH Diong","year":"2014","unstructured":"Diong SH et al (2014) Quantitation of methadone and metabolite in patients under maintenance treatment. J Anal Toxicol 38:660\u2013666","journal-title":"J Anal Toxicol"},{"key":"2766_CR31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/sj.clpt.6100120","volume":"81","author":"CB Eap","year":"2007","unstructured":"Eap CB et al (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81:719\u2013728","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR32","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/clpt.1990.37","volume":"47","author":"CB Eap","year":"1990","unstructured":"Eap CB, Cuendet C, Baumann P (1990) Binding of d-methadone, 1-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of \u03b11-acid glycoprotein. Clin Pharmacol Ther 47:338\u2013346","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR33","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","volume":"41","author":"CB Eap","year":"2002","unstructured":"Eap CB, Buclin T, Baumann P (2002) Interindividual variability of the clinical pharmacokinetics of methadone. Clin Pharmacokinet 41:1153\u20131193","journal-title":"Clin Pharmacokinet"},{"key":"2766_CR34","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archinte.166.12.1280","volume":"166","author":"GB Ehret","year":"2006","unstructured":"Ehret GB et al (2006) Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 166:1280\u20131287","journal-title":"Arch Intern Med"},{"key":"2766_CR35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10840-008-9280-8","volume":"23","author":"JL Esses","year":"2008","unstructured":"Esses JL, Rosman J, Do LT, Schweitzer P, Hanon S (2008) Successful transition to buprenorphine in a patient with methadone-induced torsades de pointes. J Interv Cardiac Electrophysiol 23:117\u2013119","journal-title":"J Interv Cardiac Electrophysiol"},{"key":"2766_CR36","first-page":"e04658","volume":"15","author":"European Food Safety Authority (EFSA)","year":"2017","unstructured":"European Food Safety Authority (EFSA) (2017) Update: use of the benchmark dose approach in risk assessment. EFSA J 15:e04658","journal-title":"EFSA J"},{"key":"2766_CR37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.vascn.2012.03.004","volume":"66","author":"L Ewart","year":"2012","unstructured":"Ewart L et al (2012) How do the top 12 pharmaceutical companies operate safety pharmacology? J Pharmacol Toxicol Methods 66:66\u201370","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2766_CR38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","volume":"142","author":"L Ewart","year":"2014","unstructured":"Ewart L et al (2014) The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative. Toxicol Sci 142:427\u2013435","journal-title":"Toxicol Sci"},{"key":"2766_CR39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00952990.2013.804525","volume":"39","author":"A Fareed","year":"2013","unstructured":"Fareed A, Vayalapalli S, Scheinberg K, Gale R, Casarella J, Drexler K (2013) QTc interval prolongation for patients in methadone maintenance treatment: a five years follow-up study. Am J Drug Alcohol Abuse 39:235\u2013240","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2766_CR40","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.273","volume":"91","author":"J Florian","year":"2012","unstructured":"Florian J, Garnett C, Nallani S, Rappaport B, Throckmorton D (2012) A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clin Pharmacol Ther 91:666\u2013672","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR41","unstructured":"Foster DJ (2001) An examination of the metabolism and pharmacokinetics of methadone with respect to stereoselectivity. Dissertation, The Universtiy of Adelaide."},{"key":"2766_CR42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2125.2000.00272.x","volume":"50","author":"DJ Foster","year":"2000","unstructured":"Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F (2000) Steady-state pharmacokinetics of (R)-and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 50:427\u2013440","journal-title":"Br J Clin Pharmacol"},{"key":"2766_CR43","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2125.2004.02079.x","volume":"57","author":"DJ Foster","year":"2004","unstructured":"Foster DJ, Somogyi AA, White JM, Bochner F (2004) Population pharmacokinetics of (R)-,(S)-and rac-methadone in methadone maintenance patients. Br J Clin Pharmacol 57:742\u2013755","journal-title":"Br J Clin Pharmacol"},{"key":"2766_CR44","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jpainsymman.2006.02.010","volume":"32","author":"OMS Fredheim","year":"2006","unstructured":"Fredheim OMS, Borchgrevink PC, Hegren\u00e6s L, Kaasa S, Dale O, Klepstad P (2006) Opioid switching from morphine to methadone causes a minor but not clinically significant increase in QTc time: a prospective 9-month follow-up study. J Pain Symptom Manag 32:180\u2013185","journal-title":"J Pain Symptom Manag"},{"key":"2766_CR45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/CIRCRESAHA.118.311209","volume":"123","author":"P Garg","year":"2018","unstructured":"Garg P, Garg V, Shrestha R, Sanguinetti MC, Kamp TJ, Wu JC (2018) Human induced pluripotent stem cell\u2013derived cardiomyocytes as models for cardiac channelopathies: a primer for non-electrophysiologists. Circ Res 123:224\u2013243","journal-title":"Circ Res"},{"key":"2766_CR46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5414\/CPP38035","volume":"38","author":"M Garrido","year":"2000","unstructured":"Garrido M, Aguirre C, Troconiz I, Marot M, Valle M, Zamacona M, Calvo R (2000) Alpha 1-acid glycoprotein (AAG) and serum protein binding of methadone in heroin addicts with abstinence syndrome. Int J Clin Pharmacol Ther 38:35\u201340","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2766_CR47","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00042560-200106010-00010","volume":"27","author":"JG Gerber","year":"2001","unstructured":"Gerber JG et al (2001) Effect of ritonavir\/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS clinical trials group (ACTG) 401. J Acquir Immune Defic Syndr (1999) 27:153\u2013160","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"2766_CR48","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/toxsci\/kft113","volume":"134","author":"K Harris","year":"2013","unstructured":"Harris K, Aylott M, Cui Y, Louttit JB, McMahon NC, Sridhar A (2013) Comparison of electrophysiological data from human-induced pluripotent stem cell\u2013derived cardiomyocytes to functional preclinical safety assays. Toxicol Sci 134:412\u2013426","journal-title":"Toxicol Sci"},{"key":"2766_CR49","first-page":"36","volume":"32","author":"CB Heesch","year":"2015","unstructured":"Heesch CB, Copfer AE, Davis SJ, Edwards BW (2015) Evaluation of methadone-induced QTc prolongation in a veteran population. Federal Pract 32:36","journal-title":"Federal Pract"},{"key":"2766_CR50","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1007\/s00216-012-6460-2","volume":"405","author":"Y-C Hsu","year":"2013","unstructured":"Hsu Y-C et al (2013) Methadone concentrations in blood, plasma, and oral fluid determined by isotope-dilution gas chromatography\u2013mass spectrometry. Anal Bioanal Chem 405:3921\u20133928","journal-title":"Anal Bioanal Chem"},{"key":"2766_CR51","first-page":"226","volume":"14","author":"Z Huang","year":"2013","unstructured":"Huang Z, Ung T (2013) Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab 14:226\u2013238","journal-title":"Curr Drug Metab"},{"key":"2766_CR52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bcpt.12239","volume":"115","author":"R Judson","year":"2014","unstructured":"Judson R et al (2014) In vitro and modelling approaches to risk assessment from the US Environmental Protection Agency ToxCast programme. Basic Clin Pharmacol Toxicol 115:69\u201376","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2766_CR53","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1360-0443.2006.01512.x","volume":"101","author":"D Justo","year":"2006","unstructured":"Justo D, Gal-Oz A, Paran Y, Goldin Y, Zeltser D (2006) Methadone-associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid-dependent patients. Addiction 101:1333\u20131338","journal-title":"Addiction"},{"key":"2766_CR54","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.110.003723","volume":"62","author":"P Kannankeril","year":"2010","unstructured":"Kannankeril P, Roden DM, Darbar D (2010) Drug-induced long QT syndrome. Pharmacol Rev 62:760\u2013781","journal-title":"Pharmacol Rev"},{"key":"2766_CR55","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.102.038240","volume":"303","author":"AN Katchman","year":"2002","unstructured":"Katchman AN, McGroary KA, Kilborn MJ, Kornick CA, Manfredi PL, Woosley RL, Ebert SN (2002) Influence of opioid agonists on cardiac humanether-a-go-go-related gene K+ currents. J Pharmacol Exp Ther 303:688\u2013694","journal-title":"J Pharmacol Exp Ther"},{"key":"2766_CR56","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bcp.12207","volume":"77","author":"AB Ke","year":"2014","unstructured":"Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD (2014) Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol 77:554\u2013570","journal-title":"Br J Clin Pharmacol"},{"key":"2766_CR57","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cpdd.326","volume":"6","author":"ED Kharasch","year":"2017","unstructured":"Kharasch ED (2017) Current concepts in methadone metabolism and transport. Clin Pharmacol Drug Dev 6:125\u2013134","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2766_CR58","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.clpt.2004.05.003","volume":"76","author":"ED Kharasch","year":"2004","unstructured":"Kharasch ED, Hoffer C, Whittington D, Sheffels P (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76:250\u2013269","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2008.12.009","volume":"101","author":"ED Kharasch","year":"2009","unstructured":"Kharasch ED, Walker A, Whittington D, Hoffer C, Bedynek PS (2009) Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity. Drug Alcohol Depend 101:158\u2013168","journal-title":"Drug Alcohol Depend"},{"key":"2766_CR60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vascn.2017.02.001","volume":"85","author":"T Kitaguchi","year":"2017","unstructured":"Kitaguchi T et al (2017) CSAHi study: detection of drug-induced ion channel\/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes. J Pharmacol Toxicol Methods 85:73\u201381","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2766_CR61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7326\/0003-4819-137-6-200209170-00010","volume":"137","author":"MJ Krantz","year":"2002","unstructured":"Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS (2002) Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137:501\u2013504","journal-title":"Ann Intern Med"},{"key":"2766_CR62","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1592\/phco.2005.25.11.1523","volume":"25","author":"MJ Krantz","year":"2005","unstructured":"Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH (2005) Effects of methadone on QT-interval dispersion. Pharmacotherapy 25:1523\u20131529","journal-title":"Pharmacotherapy"},{"key":"2766_CR63","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1039\/C7NP00014F","volume":"34","author":"JM Kratz","year":"2017","unstructured":"Kratz JM, Grienke U, Scheel O, Mann SA, Rollinger JM (2017) Natural products modulating the hERG channel: heartaches and hope. Nat Prod Rep 34:957\u2013980","journal-title":"Nat Prod Rep"},{"key":"2766_CR64","doi-asserted-by":"crossref","first-page":"339a","DOI":"10.1016\/j.bpj.2009.12.1835","volume":"98","author":"YA Kuryshev","year":"2010","unstructured":"Kuryshev YA, Kirsch GE, Brown AM (2010) Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels. Biophys J 98:339a","journal-title":"Biophys J"},{"issue":"1","key":"2766_CR65","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000167043","volume":"113","author":"C Lin","year":"2009","unstructured":"Lin C, Somberg T, Molnar J, Somberg J (2009) The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology 113(1):59\u201365","journal-title":"Cardiology"},{"key":"2766_CR66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.00559-06","volume":"51","author":"P Liu","year":"2007","unstructured":"Liu P, Foster G, LaBadie R, Somoza E, Sharma A (2007) Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy. Antimicrob Agents Chemother 51:110\u2013118","journal-title":"Antimicrob Agents Chemother"},{"key":"2766_CR67","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00204-015-1651-1","volume":"90","author":"X Li","year":"2016","unstructured":"Li X, Zhang R, Zhao B, Lossin C, Cao Z (2016) Cardiotoxicity screening: a review of rapid-throughput in vitro approaches. Arch Toxicol 90:1803\u20131816","journal-title":"Arch Toxicol"},{"key":"2766_CR68","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.toxlet.2016.11.017","volume":"266","author":"H Li","year":"2017","unstructured":"Li H, Zhang M, Vervoort J, Rietjens IMCM, van Ravenzwaay B, Louisse J (2017) Use of physiologically based kinetic modeling-facilitated reverse dosimetry of in vitro toxicity data for prediction of in vivo developmental toxicity of tebuconazole in rats. Toxicol Lett 266:85\u201393","journal-title":"Toxicol Lett"},{"key":"2766_CR69","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/toxsci\/kfq270","volume":"118","author":"J Louisse","year":"2010","unstructured":"Louisse J et al (2010) The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Toxicol Sci 118:470\u2013484","journal-title":"Toxicol Sci"},{"key":"2766_CR70","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/acs.chemrestox.6b00302","volume":"30","author":"J Louisse","year":"2017","unstructured":"Louisse J, Beekmann K, Rietjens IMCM (2017) Use of physiologically based kinetic modeling-based reverse dosimetry to predict in vivo toxicity from in vitro data. Chem Res Toxicol 30:114\u2013125","journal-title":"Chem Res Toxicol"},{"key":"2766_CR71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/J354v19n04_05","volume":"19","author":"RA Lugo","year":"2005","unstructured":"Lugo RA, Satterfield KL, Kern SE (2005) Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 19:13\u201324","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2766_CR72","doi-asserted-by":"crossref","first-page":"H2006","DOI":"10.1152\/ajpheart.00694.2011","volume":"301","author":"J Ma","year":"2011","unstructured":"Ma J et al (2011) High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol 301:H2006\u2013H2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2766_CR73","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000081416","volume":"11","author":"I Maremmani","year":"2005","unstructured":"Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A (2005) QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 11:44\u201349","journal-title":"Eur Addict Res"},{"key":"2766_CR74","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.amjcard.2004.11.055","volume":"95","author":"BA Martell","year":"2005","unstructured":"Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN (2005) Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol 95:915\u2013918","journal-title":"Am J Cardiol"},{"key":"2766_CR75","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005344-200403000-00007","volume":"43","author":"RL Martin","year":"2004","unstructured":"Martin RL, McDermott JS, Salmen HJ, Palmatier J, Cox BF, Gintant GA (2004) The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: influence of multi-channel block. J Cardiovasc Pharmacol 43:369\u2013379","journal-title":"J Cardiovasc Pharmacol"},{"key":"2766_CR76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvr044","volume":"91","author":"GR Mirams","year":"2011","unstructured":"Mirams GR et al (2011) Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical torsadogenic risk. Cardiovasc Res 91:53\u201361","journal-title":"Cardiovasc Res"},{"key":"2766_CR77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2014.26","volume":"3","author":"H Mishra","year":"2014","unstructured":"Mishra H, Polak S, Jamei M, Rostami-Hodjegan A (2014) Interaction between domperidone and ketoconazole: toward prediction of consequent QTc prolongation using purely in vitro information. CPT Pharmacomet Syst Pharmacol 3:1\u201311","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"2766_CR78","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jat\/32.3.208","volume":"32","author":"DE Moody","year":"2008","unstructured":"Moody DE, Lin S-N, Chang Y, Lamm L, Greenwald MK, Ahmed MS (2008) An enantiomer-selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine, and liver microsomes. J Anal Toxicol 32:208\u2013219","journal-title":"J Anal Toxicol"},{"key":"2766_CR79","first-page":"229","volume":"4","author":"S Mujtaba","year":"2013","unstructured":"Mujtaba S, Romero J, Taub CC (2013) Methadone, QTc prolongation and torsades de pointes: current concepts, management and a hidden twist in the tale? J Cardiovasc Dis Res 4:229\u2013235","journal-title":"J Cardiovasc Dis Res"},{"key":"2766_CR80","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1254\/jphs.13248FP","volume":"124","author":"Y Nakamura","year":"2014","unstructured":"Nakamura Y et al (2014) Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell\u2013derived cardiomyocyte sheet: multi-site validation study. J Pharmacol Sci 124:494\u2013501","journal-title":"J Pharmacol Sci"},{"key":"2766_CR81","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1399-6576.1982.tb01850.x","volume":"26","author":"M-I Nilsson","year":"1982","unstructured":"Nilsson M-I, Meresaar U, \u00c4Ngg\u00e5rd E (1982) Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand 26:66\u201369","journal-title":"Acta Anaesthesiol Scand"},{"key":"2766_CR82","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00204-017-1941-x","volume":"91","author":"J Ning","year":"2017","unstructured":"Ning J, Louisse J, Spenkelink B, Wesseling S, Rietjens IMCM (2017) Study on inter-ethnic human differences in bioactivation and detoxification of estragole using physiologically based kinetic modeling. Arch Toxicol 91:3093\u20133108","journal-title":"Arch Toxicol"},{"key":"2766_CR119","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.yrtph.2017.06.006","volume":"88","author":"Y Nozaki","year":"2017","unstructured":"Nozaki Y et al (2017) CSAHi study-2: validation of multi-electrode array systems (MEA60\/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: assessment of reference compounds and comparison with non-clinical studies and clinical information. Regul Toxicol Pharmacol 88:238\u2013251","journal-title":"Regul Toxicol Pharmacol"},{"key":"2766_CR83","first-page":"1021","volume":"298","author":"Y Oda","year":"2001","unstructured":"Oda Y, Kharasch ED (2001) Metabolism of methadone andlevo-\u03b1-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther 298:1021\u20131032","journal-title":"J Pharmacol Exp Ther"},{"key":"2766_CR84","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/cpt1973143338","volume":"14","author":"GD Olsen","year":"1973","unstructured":"Olsen GD (1973) Methadone binding to human plasma proteins. Clin Pharmacol Ther 14:338\u2013343","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR85","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/CIRCRESAHA.119.315378","volume":"125","author":"L Pang","year":"2019","unstructured":"Pang L et al (2019) Workshop report: FDA workshop on improving cardiotoxicity assessment with human-relevant platforms. Circ Res 125:855\u2013867","journal-title":"Circ Res"},{"key":"2766_CR86","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1360-0443.2006.01668.x","volume":"102","author":"E Peles","year":"2007","unstructured":"Peles E, Bodner G, Kreek MJ, Rados V, Adelson M (2007) Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients\u2014a cross-sectional study. Addiction 102:289\u2013300","journal-title":"Addiction"},{"key":"2766_CR87","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/jpm.2009.0184","volume":"13","author":"S Reddy","year":"2010","unstructured":"Reddy S, Hui D, Osta BE, de la Cruz M, Walker P, Palmer JL, Bruera E (2010) The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med 13:33\u201338","journal-title":"J Palliat Med"},{"key":"2766_CR88","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","volume":"58","author":"W Redfern","year":"2003","unstructured":"Redfern W et al (2003) Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32\u201345","journal-title":"Cardiovasc Res"},{"key":"2766_CR89","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.3390\/ijms18122634","volume":"18","author":"S Rehnelt","year":"2017","unstructured":"Rehnelt S et al (2017) Frequency-dependent multi-well cardiotoxicity screening enabled by optogenetic stimulation. Int J Mol Sci 18:2634","journal-title":"Int J Mol Sci"},{"key":"2766_CR90","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/mnfr.201000655","volume":"55","author":"IMCM Rietjens","year":"2011","unstructured":"Rietjens IMCM, Louisse J, Punt A (2011) Tutorial on physiologically based kinetic modeling in molecular nutrition and food research. Mol Nutr Food Res 55:941\u2013956","journal-title":"Mol Nutr Food Res"},{"key":"2766_CR91","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/clpt.1981.34","volume":"29","author":"M Romach","year":"1981","unstructured":"Romach M, Piafsky K, Abel J, Khouw V, Sellers E (1981) Methadone binding to orosomucoid (\u03b11-acid glycoprotein): Determinant of free fraction in plasma. Clin Pharmacol Ther 29:211\u2013217","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR92","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1360-0443.2011.03767.x","volume":"107","author":"AK Roy","year":"2012","unstructured":"Roy AK, McCarthy C, Kiernan G, McGorrian C, Keenan E, Mahon NG, Sweeney B (2012) Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. Addiction 107:1132\u20131139","journal-title":"Addiction"},{"key":"2766_CR93","first-page":"e55587","volume":"123","author":"L Sala","year":"2017","unstructured":"Sala L, Ward-van Oostwaard D, Tertoolen LG, Mummery CL, Bellin M (2017) Electrophysiological analysis of human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) using multi-electrode arrays (MEAs). J Vis 123:e55587","journal-title":"J Vis"},{"key":"2766_CR94","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nrd3287","volume":"9","author":"DA Smith","year":"2010","unstructured":"Smith DA, Di L, Kerns EH (2010) The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat Rev Drug Discov 9:929\u2013939","journal-title":"Nat Rev Drug Discov"},{"key":"2766_CR95","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.drudis.2008.11.009","volume":"14","author":"JL Stevens","year":"2009","unstructured":"Stevens JL, Baker TK (2009) The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today 14:162\u2013167","journal-title":"Drug Discov Today"},{"key":"2766_CR96","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00204-013-1107-4","volume":"87","author":"M Strikwold","year":"2013","unstructured":"Strikwold M, Spenkelink B, Woutersen RA, Rietjens IMCM, Punt A (2013) Combining in vitro embryotoxicity data with physiologically based kinetic (PBK) modelling to define in vivo dose\u2013response curves for developmental toxicity of phenol in rat and human. Arch Toxico 87:1709\u20131723","journal-title":"Arch Toxico"},{"key":"2766_CR97","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1007\/s00204-016-1881-x","volume":"91","author":"M Strikwold","year":"2017","unstructured":"Strikwold M, Spenkelink B, de Haan LH, Woutersen RA, Punt A, Rietjens IMCM (2017) Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols. Arch Toxicol 91:2119\u20132133","journal-title":"Arch Toxicol"},{"key":"2766_CR98","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2146\/ajhp070392","volume":"66","author":"J Stringer","year":"2009","unstructured":"Stringer J, Welsh C, Tommasello A (2009) Methadone-associated QT interval prolongation and torsades de pointes. Am J Health Syst Pharm 66:825\u2013833","journal-title":"Am J Health Syst Pharm"},{"key":"2766_CR99","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm00266a009","volume":"16","author":"HR Sullivan","year":"1973","unstructured":"Sullivan HR, Due SL (1973) Urinary metabolites of dl-methadone in maintenance subjects. J Med Chem 16:909\u2013913","journal-title":"J Med Chem"},{"key":"2766_CR100","first-page":"139","volume-title":"Acute phase proteins","author":"K Taguchi","year":"2013","unstructured":"Taguchi K, Nishi K, Chuang VTG, Maruyama T, Otagiri M (2013) Molecular aspects of human alpha-1 acid glycoprotein\u2014structure and function. In: Janciauskiene S (ed) Acute phase proteins. InTech, Croatia, pp 139\u2013162"},{"key":"2766_CR101","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2005a) S7B: The non-clinical evaluation of the potential for delayed ventricular re-polarization (QT interval prolongation) by human pharmaceuticals. https:\/\/database.ich.org\/sites\/default\/files\/S7B_Guideline.pdf. Accessed 20 Nov 2019"},{"key":"2766_CR102","unstructured":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2005b) E14: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. https:\/\/database.ich.org\/sites\/default\/files\/E14_Guideline.pdf. Accessed 20 Nov 2019"},{"key":"2766_CR103","unstructured":"Thermo Fisher Scientific (2017) User Guide: Single-Use RED Plate with Inserts. https:\/\/assets.thermofisher.com\/TFS-Assets\/LSG\/manuals\/MAN0011619_SgleUse_RED_Plate_Insert_UG.pdf. Accessed 20 Nov 2019"},{"key":"2766_CR104","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/ALN.0b013e3181642938","volume":"108","author":"RA Totah","year":"2008","unstructured":"Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108:363\u2013374","journal-title":"Anesthesiology"},{"key":"2766_CR105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/jpp.JPP_163_17","volume":"9","author":"JM Treece","year":"2018","unstructured":"Treece JM et al (2018) Comprehensive review on methadone-induced QT prolongation and torsades. J Pharmacol Pharmacother 9:66","journal-title":"J Pharmacol Pharmacother"},{"key":"2766_CR106","doi-asserted-by":"crossref","first-page":"e003264","DOI":"10.1161\/JAHA.116.003264","volume":"5","author":"B Vandenberk","year":"2016","unstructured":"Vandenberk B et al (2016) Which QT correction formulae to use for QT monitoring? J Am Heart Assoc 5:e003264","journal-title":"J Am Heart Assoc"},{"key":"2766_CR107","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jala.2010.06.002","volume":"16","author":"S van Liempd","year":"2011","unstructured":"van Liempd S, Morrison D, Sysmans L, Nelis P, Mortishire-Smith R (2011) Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding JALA. J Assoc Lab Autom 16:56\u201367","journal-title":"J Assoc Lab Autom"},{"key":"2766_CR108","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/cpt1975182180","volume":"18","author":"K Verebely","year":"1975","unstructured":"Verebely K, Volavka J, Mul\u00e9 S, Resnick R (1975) Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 18:180\u2013190","journal-title":"Clin Pharmacol Ther"},{"key":"2766_CR109","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1472-8206.2002.00099.x","volume":"16","author":"ID Wakefield","year":"2002","unstructured":"Wakefield ID, Pollard C, Redfern WS, Hammond TG, Valentin JP (2002) The application of in vitro methods to safety pharmacology. Fundam Clin Pharmacol 16:209\u2013218","journal-title":"Fundam Clin Pharmacol"},{"key":"2766_CR110","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1002\/jps.21317","volume":"97","author":"NJ Waters","year":"2008","unstructured":"Waters NJ, Jones R, Williams G, Sohal B (2008) Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J Pharm Sci 97:4586\u20134595","journal-title":"J Pharm Sci"},{"key":"2766_CR111","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.167.22.2469","volume":"167","author":"EF Wedam","year":"2007","unstructured":"Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC (2007) QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 167:2469\u20132475","journal-title":"Arch Intern Med"},{"key":"2766_CR112","first-page":"659","volume":"27","author":"MW Wheeler","year":"2007","unstructured":"Wheeler MW, Bailer AJ (2007) Properties of model-averaged BMDLs: a study of model averaging in dichotomous response risk estimation risk analysis. Int J 27:659\u2013670","journal-title":"Int J"},{"key":"2766_CR113","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00007691-199702000-00015","volume":"19","author":"JN Wilkins","year":"1997","unstructured":"Wilkins JN, Ashofteh A, Setoda D, Wheatley WS, Huigen H, Ling W (1997) Ultrafiltration using the Amicon MPS-1 for assessing methadone plasma protein binding. Ther Drug Monit 19:83\u201387","journal-title":"Ther Drug Monit"},{"key":"2766_CR114","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1046\/j.1360-0443.2000.951217717.x","volume":"95","author":"K Wolff","year":"2000","unstructured":"Wolff K, Rostami-Hodjegan A, Hay A, Raistrick D, Tucker G (2000) Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 95:1771\u20131783","journal-title":"Addiction"},{"key":"2766_CR115","unstructured":"World Health Organization (WHO). (2010). Characterization and application of physiologically based pharmacokinetic models in risk assessment. https:\/\/www.inchem.org\/documents\/harmproj\/harmproj\/harmproj9.pdf. Accessed 20 Nov 2019"},{"key":"2766_CR116","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10928-006-9018-0","volume":"33","author":"F Yang","year":"2006","unstructured":"Yang F, Tong X, McCarver DG, Hines RN, Beard DA (2006) Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 33:485\u2013518","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2766_CR117","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/toxsci\/kfz134","volume":"171","author":"S Zhao","year":"2019","unstructured":"Zhao S, Kamelia L, Boonpawa R, Wesseling S, Spenkelink B, Rietjens IMCM (2019) Physiologically based kinetic modeling-facilitated reverse dosimetry to predict in vivo red blood cell acetylcholinesterase inhibition following exposure to chlorpyrifos in the Caucasian and Chinese population. Toxicol Sci 171:69\u201383","journal-title":"Toxicol Sci"},{"key":"2766_CR118","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.yjmcc.2019.09.007","volume":"136","author":"A Zwartsen","year":"2019","unstructured":"Zwartsen A, de Korte T, Nacken P, de Lange DW, Westerink RH, Hondebrink L (2019) Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings. J Mol Cell Cardiol 136:102\u2013112","journal-title":"J Mol Cell Cardiol"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-020-02766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-020-02766-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-020-02766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T19:15:58Z","timestamp":1620069358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-020-02766-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":118,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2766"],"URL":"https:\/\/doi.org\/10.1007\/s00204-020-02766-7","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"26 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The manuscript does not contain clinical human or animal studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}